The Business of Cannabis: New York Summit returns to Williamsburg on Wednesday, November 6, bringing together 300 of the most influential figures shaping the future of cannabis in New York, and across the United States.

Despite headlines, rescheduling cannabis in the US is a complex, multi-agency process involving FDA, DEA, DOJ, and international treaty obligations—presidential action alone isn’t enough. Read here:

.@Curaleaf_Labs has announced the launch of the UK’s first CE-certified liquid medical cannabis inhaler, aiming to address growing patient and clinical demand for a discreet and reliable inhalation method. Read the full article:

Pressure is mounting on the Trump administration to take a clear stance on cannabis as two upcoming Supreme Court cases could force its hand.

The Texas Senate has passed SB 6, a bill banning intoxicating hemp-derived products like delta-8 THCdefying Gov. Abbott’s call for regulation. #CannabisIndustry #HempPolicy #SB6 #TexasPolitics #THCRegulation.

Nearly 80% of Canadian’s now source their cannabis solely from the legal market, marking a stark shift away from the illicit market seven years after legalisation.

New York’s adult-use cannabis industry faces another major hurdle. A federal appeals court ruled the state’s licensing priority for applicants with NY cannabis convictions unconstitutional. Can New York protect its equity-focused cannabis program?.

New research funded by Pure Sunfarms confirms what many cultivators have long suspected: cannabis flower potency isn’t fixed. THC levels can vary by up to a third—even within the same plant—making exact labelling inherently inaccurate. ✍️ @MJBizDaily

The President’s first public remarks on the long-stalled #rescheduling project have reignited investor enthusiasm across North America. But will political momentum translate into policy change? .

President Trump promises a cannabis rescheduling decision “in the next few weeks.” Optimism grows, but past delays fuel doubt—will this lead to real reform or another cycle of unmet expectations?.

Business of Cannabis Podcast 🎙 . Guest Episode 6 | @releaf_uk x Professor Chris Shambrook. Watch on YouTube: .Listen on Spotify: .Listen on Apple:

BofC returns to New York for our fourth consecutive year this November, with a NEW premium format to elevate your conference schedule with a VIP experience. 💼 Power Networking.🤝 Executive Exchanges.💸 Deal Flow Zone. 🎟️ Join us on November 6

A major policy win for the US hemp industry: Controversial language that could have banned up to 95% of hemp products, including popular THC analogues like delta-8, has been removed from the Senate Agriculture-FDA appropriations bill.

New York's cannabis industry is understandably furious after the OCM conceded that for two years they had been misapplying zoning laws, meaning over 100 licensees are now in violation and could be forced to relocate.

Over two dozen cannabis testing labs have refiled a $1B lawsuit against Revvity, alleging it knowingly sold equipment unfit for cannabis testing. The case could reshape how the industry approaches lab standards and supplier accountability.

A major showdown is unfolding in Texas that could reshape the future of hemp regulation across the US. Senate Bill 5 proposes a sweeping ban on all hemp products containing detectable THC—threatening an industry that employs 50,000 people statewide.

A new phase of US #cannabis enforcement is now underway in the US, and Deb Tharp writes that recent #ICEraids, regulatory pivots, and conservative policy blueprints like #Project2025 are not isolated events but part of a broader, coordinated shift.

Terrance Cole, has been confirmed as the new permanent head of the Drug Enforcement Administration (DEA), and will now be responsible for the oversight of the landmark cannabis rescheduling project.

The US cannabis rescheduling process has stalled for over six months, and new federal budget rules now block funding for any progress. With 38 states allowing medical cannabis, what will this mean for the industry’s future?.

Outrage and rancor swelled Friday after federal immigration raids at two state-licensed cannabis cultivation sites in Southern California operated by publicly traded Glass House Brands. This story was originally published on MJBiz Daily.